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Background: In 2009, a worldwide supply constraint of imiglucerase led to treatment modifications or interruptions
for patients with Gaucher disease (GD) type 1. In France, joint treatment recommendations were issued to protect
the most vulnerable patients. This observational study evaluated the impact of imiglucerase treatment modifications
on the clinical and biological course of GD.
Methods: Retrospective data on patients’ characteristics, treatment, clinical and biological parameters from 01 June
2009 to 31 October 2010 were collected during a single visit.
Results: Ninety-nine GD1 patients, aged 7–84 years, were included (median age 47 years); 10 were children.
Patients experienced a median of 4 different treatment modifications. Median change from pre-supply constraint
dose (92 U/kg/4-weeks) was −69, −51, −29 and −60 U/kg/4-weeks at 3, 6, 9 and 12 months after first modification,
respectively, with imiglucerase discontinuation reported for 70%, 47%, 29% and 55% of patients at these timepoints.
Replacement with another ERT was reported for 35 patients. Results show a statistically significant decrease in
hemoglobin (−0.8 g/L/month) and platelets (−5905.103/mm3/month) and an increase in chitotriosidase (+537 nmol/
mL/h/month) and angiotensin-converting enzyme (+4 IU/L/month) in the subgroup of 61 patients who discontinued
treatment for at least 3 months; this magnitude of change was not seen in the subgroup (32 patients) treated with
reduced imiglucerase for at least 3 consecutive months. GD-related events were spontaneously reported by the
study investigators for 39% of the whole study population, including asthenia/fatigue (8%), bone infarction and
bone pain (4% each), and hepatomegaly (3%). A Kaplan-Meier estimate of the probability for a patient to present a
bone, hematological or visceral event during the constraint was 37% for patients who discontinued the treatment
and 10% for patients treated with a reduced imiglucerase dose.
Conclusion: The release of recommendations and individuals’ close follow-up allowed satisfactory management
of patients during the imiglucerase supply constraint in France. This study suggests that during this period, lowering
the dose of imiglucerase had less impact on the outcomes of patients than interrupting treatment. However,
general effects (such as fatigue, bone pain) reported in some patients, emphasize the importance of maintaining
appropriate individualized dosing.
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Gaucher Disease (GD) is an inherited lysosomal storage
disease, attributable to glucocerebrosidase enzyme de-
ficiency; in rare cases, the absence of saposin C, an ac-
tivator of glucocerebrosidase, leads to a Gaucher-like
disorder [1]. GD is a rare autosomal recessive disease
with an incidence between 1/50,000 and 1/100,000 in
the general population, though it is more prevalent in
the Ashkenazi Jew population [2]. GD is characterized
by the presence of lipid-engorged macrophages whose
nuclei are off-center (Gaucher cells). Abnormal reticu-
loendothelial cells mainly localize in the liver, spleen
and bone marrow and their accumulation leads to the
main signs of disease: hepatosplenomegaly associated
with abdominal discomfort, thrombocytopenia and co-
agulopathy leading to a bleeding tendency, anemia as-
sociated with chronic fatigue, bone lesions that may
become debilitating (e.g., chronic bone pain, bone cri-
ses, and/or bone events [pathological fractures and
vertebral collapse, bone infarcts, osteonecrosis requir-
ing hip replacement]) and decreased bone mineral
density, along with neurological disorders in some
rarer forms [3]. The age of diagnosis varies consider-
ably (from birth to 81 years), though half of patients
are under 10 years of age at the time of diagnosis [3].
The disease’s progression is also highly variable; some
patients remain asymptomatic until their adult years,
whereas others develop signs and complications during
their early childhood [4,5]. GD is traditionally classi-
fied into three clinical types according to the presence
or absence of neurological impairment [6]. The type 1
or chronic non-neuropathic form, defined by the ab-
sence of neurological findings, is the most frequent
form of the disease (94% of patients) [3], affecting both
children and adults [7]. Treatment of GD is based on
the evaluation of signs of disease progression, mainly
hematological (i.e., thrombocytopenia, anemia) and/or
visceral (i.e., splenomegaly, hepatomegaly) and/or
bone-related manifestations, described in the GD Diag-
nosis and Treatment national guidelines (PNDS) [8].
Serum chitotriosidase, tartrate-resistant acid phosphatase
(TRAP), angiotensin-converting enzyme (ACE) and ferriti-
nemia can be used to evaluate disease progression
[5,9]. In 2009, two treatments granted Marketing Au-
thorizations were available: enzyme replacement ther-
apy (ERT) using imiglucerase (Cerezyme® [Alglucerase®
before 1996], Genzyme, a SANOFI company) and sub-
strate reduction therapy (SRT) by miglustat (Zavesca®,
ACTELION). The reference treatment for GD is ERT.
The recommended posology for imiglucerase in France
at initiation of treatment is 60 U/kg/14 days [10], sub-
sequently dosing can be individualized according to the
patient’s achievement of stabilization of parameters, and the
regression or normalization of signs and/or symptoms thatinitially led to treatment indication [8,10-17]. Once insti-
tuted, ERT is generally administered for life [10,18].
Temporary manufacturing difficulties encountered at
Genzyme’s manufacturing plant led to a worldwide sig-
nificantly constrained imiglucerase supply between June
2009 and November 2010. Treatment recommendations
were implemented with the European Medicines Agency
(EMA); high-risk groups were identified and prioritized
to receive imiglucerase and included infants, children,
adolescents and adult patients at high risk for the devel-
opment of severe, life-threatening disease progression
[19,20]. In France, joint recommendations were issued
by the GD treatment evaluation committee (Comité
d’Evaluation du Traitement de la maladie de Gaucher
[CETG], the French Medicines Agency [L’Agence fran-
çaise de sécurité sanitaire du médicament et des pro-
duits de santé (Afssaps), currently L’Agence nationale
de sécurité du médicament et des produits de santé
(ANSM)], representatives of pharmaceutical compan-
ies, and representatives of patient associations (the
Vaincre les Maladies Lysosomales [VML], and French
representatives of the European Gaucher Alliance).
Similarly, close clinical and biological monitoring of
hematological parameters (hemoglobin and platelet
counts) and biomarkers (chitotriosidase) was recom-
mended during this period [21,22]. The management
of the imiglucerase supply constraint in France pro-
ceeded in several steps: first, a recommendation of a
50% dose reduction for patients with moderate disease
(June 2009), followed by a subsequent recommendation
of a 50% dose reduction in children, adolescents, GD3
patients, and pregnant women, and a switch to miglustat
or a discontinuation of imiglucerase for other patients
(Aug 2009). In September 2010, a letter from the EMA
(Direct Healthcare Professional Communication) in-
formed health care professionals of an improvement in
supply of imiglucerase such that patients who were being
treated with reduced doses could be returned to doses per
SmPC, but patients could not be initiated on imiglucerase
or switched back to imiglucerase. Under the circumstances,
two other ERTs in development at the time were rapidly
made available to French treating physicians: velaglucerase
alfa (VPriv®, SHIRE) and taliglucerase alfa (PROTALIX-PFI-
ZER). Resumption of imiglucerase production in October
2010 allowed for treatment to be progressively resumed or
doses to be adjusted to individual requirements.
The goal of this study was to evaluate the clinical and
biological impact of the imiglucerase supply constraint in
France from 01 June 2009 to 31 October 2010 (17 months).
Methods
Design and regulatory authorizations
This was an observational, retrospective, multicenter, na-
tional, non-comparative study.
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rase (Cerezyme® [Ceredase® before 1996], Genzyme-a
SANOFI company) for at least 6 months at the time of
their therapeutic scheme modification, which was due to
the imiglucerase supply constraint, could potentially be
included in this study. To this aim, all French physicians
treating at least one patient with GD at the time of the
study implementation were proposed to participate as
study investigators.
The patient (or legal guardian) was informed and
agreed to participation. The study was approved by the
French Healthcare Research Data Processing Advisory
Board, the French National Data Protection Commis-
sion, and the Institutional Review Board of Paris North
Hospitals. It was conducted in accordance with the
French Good Epidemiological Practice guidelines.
Data collected
The study comprised a single visit for each patient that
took place between May 2011 (first patient) and April
2012 (last patient). During this visit, the following data
were collected: demographic data; information about
GD history (age at time of diagnosis, phenotype, geno-
type, prior history of splenectomy, bone impairments,
and alglucerase/imiglucerase treatment history); imiglu-
cerase treatment status; biological and clinical character-
istics (notably bone manifestations) in the 6 months
preceding the first treatment modification; subsequent
changes in the imiglucerase treatment regimen (dose
modification, discontinuation, switch to other GD treat-
ments); and evolution of clinical (weight) and biological
parameters (hemoglobin and platelet counts, chitotriosi-
dase, TRAP, ferritinemia, ACE) during the course of the
constraint period. GD-related events occurring after the
first modification to the patient’s therapeutic scheme,
i.e., clinical or biological events considered potentially
related to GD (rather than treatment-related) were also
spontaneously reported by investigators. Among those,
bone events were of special interest; they were defined
in the statistical analysis plan as symptomatic bone
events (as per PNDS guidelines [8]) with a radiological
confirmation: avascular necrosis (AVN) of an epiphysis,
bone infarct, pathological fracture, or vertebral collapse.
Other GD-related events could be spontaneously re-
ported by each physician such as hematological events
(e.g., platelets and/or hemoglobin decrease) and visceral
events (e.g. liver and/or spleen volume increase).
Definition of constraint period
The absolute supply constraint period for the population
was defined as starting on 01 June 2009 and ending on
31 October 2010. The start for each patient was defined
as the date of the first imiglucerase treatment modifica-
tion on or following 01 June 2009. For each patient, theconstraint period extended from the time of first treat-
ment modification to 31 October 2010.
For each parameter, the pre-constraint value was de-
fined as the most recent evaluation within 6 months prior
to the start of treatment modification for the patient.
Statistical methods
All statistical analyses were computed with SAS software
(version 9.1; SAS Institute; Cary, North Carolina, United
States). Categorical variables were summarized using fre-
quencies and percentages. Continuous variables were
summarized by the number of non-missing observations,
mean, standard deviation, median, minimum, and max-
imum (range). Analyses were mainly descriptive and
statistical tests were performed for exploratory purposes.
A two-sided type I error rate of 0.05 was used to define
statistical significance.
The primary population for all analyses was the full
analysis set (FAS), which comprised all included patients
who had experienced a treatment modification.
Since the study patients had various treatment modifi-
cations in the course of the whole constraint period, in
order to isolate and assess the impact of imiglucerase
treatment modification on the biological and clinical
outcome of the patients, the analysis was performed on
a constraint period limited to the period during which
the treatment modification (discontinuation or reduced
dose compared to pre-constraint dose) was stable for at
least 3 consecutive months in a given patient (‘limited
constraint period’). Two subgroups of patients were de-
fined according to the first modification lasting at least 3
consecutive months:
– Subgroup 1: Discontinuation of imiglucerase without
addition of another GD treatment (i.e., miglustat
(Zavesca®, ACTELION) or another ERT).
– Subgroup 2: Treatment with a reduced imiglucerase
dose (in U/kg/4-weeks) compared to pre-constraint
dose. The changes in biological parameters over
time during the constraint period were analysed
using mixed-linear models for repeated-measures,
with intercept and slope considered as random.
Analysis of GD-related events was performed on the
FAS during the whole constraint period, and for each
subgroup during the constraint period limited to stable
modification. We described the number and nature of
GD-related bone events before and after the supply con-
straint onset, i.e., during the whole study period (from
the time of first treatment modification on or after 01
June 2009 to 31 October 2010) and during the preceding
equivalent time period (i.e., approximately 18 months,
from January 2008 to June 2009). Finally, time to occur-
rence and probability to present a bone, hematologic or
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estimated with the Kaplan-Meier method.
Results
Patients’ characteristics
The characteristics of the 99 patients with GD 1 in-
cluded in the study are described in Table 1. These pa-
tients aged from 7 to 84 years (median of 47 years);
there were slightly more male patients (52.5%). Ten pa-
tients (10%) were under 18 years old. A splenectomy
had been performed for 30% of the patients (partial for
one patient). During the 18 months preceding the initial
therapeutic scheme modification, we identified 16 boneTable 1 Patients characteristics at baseline, overall and for tw









Age (years) 99 61
At inclusion 47 (7; 84)
At GD diagnosis 20 (1; 64)
Weight (kg) 85 66 (29; 105) 51
Genotyping performed 99 56 (56.6%) 61






Treated with alglucerase before 1996 99 23 (23.2%) 61
Hepatomegaly 98 30 (30.6%) 60
Splenectomy 99 30 (30.3%) 61
Splenomegaly in
non-splenectomized patients
69 25 (36.2%) 40
Asthenia 99 30 (30.3%) 61
Other clinical manifestation(s) 99 15 (15.2%) 61
Concomitant disease 99 38 (38.4%) 61
Bone impairment 99 33 (33.3%) 61
Hemoglobin (g/L) 85 140 (104; 163) 52
Platelets (103/mm3) 86 182.5 (48; 478) 52
Ferritin (μg/L) 50 221 (16; 2310) 33
Chitotriosidase (nmol/mL/h) 64 730 (3; 16300) 38
ACE (IU/L) 42 51.5 (10; 252) 26
*6 patients are not reported in the subgroups: 2 patients could not be classified (no
only miglustat for at least 3 consecutive months.
n: number of patients with available data.events (5 AVN, 10 bone infarcts and 1 vertebral com-
pression) in 12 patients. Evaluation within the 6 months
preceding the initial therapeutic scheme modification
(pre-constraint timepoint) showed splenomegaly for 36%
of the 69 non-splenectomized patients. Hepatomegaly
and asthenia were reported for 30 patients each (30%).
Bone impairment was reported for 33% of the patients,
consisting mainly of localized bone pain (55% of the
cases) and osteoporosis (21%). No recent bone crisis or
fractures were reported during this timeframe. Other
clinical manifestations were reported for 15 patients
(15%; mainly gingival bleeding), and concomitant dis-
eases were reported for 38 patients (38%; mainlyo subgroups
o discontinued imiglucerase
3 consecutive months
Patients receiving a reduced 4-week
imiglucerase dose for at least 3
consecutive months (N = 32)
Median (range) or
n (%) patients
n Median (range) or
n (%) patients
32
32 (52.5%) 17 (53.1%)
29 (47.5%) 15 (46.9%)
32
47 (22 ; 84) 30 (7; 71)
23 (2; 61) 8.5 (1; 64)
72 (45; 105) 28 60 (29; 92)




5 (14.3%) 2 (11.1%)
10 (28.6%) 13 (72.2%)
8 (22.9%) 3 (16.7%)
13 (21.3%) 32 8 (25.0%)
18 (30.0%) 32 9 (28.1%)
21 (34.4%) 32 7 (21.9%)
13 (32.5%) 25 10 (40.0%)
20 (32.8%) 32 7 (21.9%)
7 (11.5%) 32 6 (18.8%)
25 (41.0%) 32 11 (34.4%)
22 (36.1%) 32 8 (25.0%)
143 (106; 163) 27 134 (104; 154)
179.5 (48; 478) 28 185 (59; 415)
216 (16; 1150) 13 275 (29; 2310)
234 (14; 16300) 20 1251 (3; 10170)
42.5 (10; 252) 13 70 (19; 171)
stable modification for at least 3 consecutive months) and 4 patients took
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mostly comparable for patients who discontinued imi-
glucerase and for patients who were treated with a re-
duced dose for at least 3 consecutive months, excepting
median age because none of the pediatric patients dis-
continued imiglucerase.
Treatment modifications
The first treatment modification (i.e., on or following 01
June 2009) took place at a mean time of 8 (±4) years
after imiglucerase initiation. The doses of imiglucerase
provided during the constraint period are presented in
Table 2. Overall, the median dose of imiglucerase was
116 U/kg/4-weeks (range: 51; 267) at treatment initiation
and 92 U/kg/4-weeks (range: 10; 239) prior to modifica-
tion. At the first modification, the median dose of imi-
glucerase decreased to 40 U/kg/4-weeks, with a median
absolute reduction of −52 U/kg/4-weeks (range: −127;
−6). At 3, 6 and 9 months after the first modification,
the dose of imiglucerase ranged from 0 (discontinuation)
to a maximum of 170 U/kg/4-weeks, with a median
absolute change of 69, −51 and −29 U/kg/4-weeks, re-
spectively. Twelve months after the first modification,
the imiglucerase dose ranged from 0 to 129 U/kg/4-
weeks, with the median dose of 0 due to 55% of the pa-
tients having discontinued treatment with imiglucerase.
Similar results were observed at the last modification
prior to 01 November 2010, with 58% of patients having
discontinued treatment with imiglucerase and doses ran-
ging from 0 to 160 U/kg/4-weeks. When the patients
who discontinued treatment (dose = 0) were excluded,
the median dose of imiglucerase was 49 U/kg/4-weeks
(range: 14; 181) at the first modification, progressively
increasing overtime to 84 U/kg/4-weeks (range: 14; 160)
at the last modification.
For the overall population of GD 1 patients included
in this study, the mean duration of modification was 15
(±2) months. During this period, treatment modifica-
tions reached a median number of 4, with a median
average duration of approximately 4 months for eachTable 2 Evolution of imiglucerase dose during the supply con
Dose of imiglucerase
n Mean (SD)
Pre-constraint (in the 6 months prior
to first modification)
94 92.5 (33.5)
First modification on or after 01 Jun 2009 99 35.0 (32.0)
Time interval after the first modification: 3 months 98 17.5 (29.4)
6 months 95 41.0 (42.8)
9 months 95 55.9 (45.0)
12 months 96 37.3 (45.5)
Last modification prior to 01 Nov 2010 98 37.6 (47.3)
n: number of patients with available data; SD: standard deviation; Range: minimumpatient. The treatment was modified once for 7 patients
(7%), twice for 16 patients (16%), between three and six
times for 59 patients (60%) and more than six times for
17 patients (17%). The types of modification over time
(i.e., for a given patient, from the date of first modifica-
tion until 31 October 2010) are presented in Figure 1.
Discontinuation of imiglucerase treatment without intro-
duction of another treatment was reported for 32 patients
at the first modification and for 63 patients 3 months after
the first modification. Discontinuation of imiglucerase
treatment progressively decreased to 15 patients by the
last modification prior to 1 November 2010. At this last
time point, replacement of imiglucerase by another ERT
was reported for 35 patients (velaglucerase for 25 patients
and taliglucerase for 10 patients).
A dose reduction of 50% or more was reported for 30
patients (31%) at the first modification and 5 to 10 pa-
tients at subsequent timepoints. At 6 months after the
first modification and at subsequent timepoints, 4% to
8% of the patients could return to the pre-constraint
dose, and 14% to 18% of the patients were treated with
higher doses compared to pre-constraint doses.
Evaluation of the impact of imiglucerase treatment
modifications on the disease
The progression of the biological parameters was
assessed on a period limited to the duration of the first
stable modification. This period lasted 3 to 15 months
depending on each individual, with a median of 5 months
in the subgroup of 61 patients who discontinued imiglu-
cerase, and a median of 6 months in the subgroup of 32
patients treated with a reduced dose (6 patients could
not be analysed in either of the subgroups as they had
no such stable modification).
Biological parameters
The results of mixed linear models used to assess the
development of biological parameters are presented in
Table 3. These results must be analysed with caution
due to the limited available data and variability in thestraint period
(U/kg/4-weeks) Change from pre-constraint dose (U/kg/4-weeks)
Median (range) n Mean (SD) Median (range)
92 (10; 239)
40 (0; 181) 94 −55.9 (28.9) −52 (−127; −6)
0 (0; 160) 93 −74.1 (38.6) −69 (−223; 0)
49 (0; 160) 91 −51.1 (51.6) −51 (−223; 62)
56 (0; 170) 90 −36.6 (48.1) −29 (−223; 62)
0 (0; 129) 91 −55.8 (52.2) −60 (−223; 62)





































dose increased compared to pre-
constraint dose
return to pre-constraint dose
dose reduced compared to pre-
constraint dose
treatment discontinuation and




introduction of another treatment
(n patients for each type of modification)After the first modification
Figure 1 Number (bars) and percentage (y-axis) of patients for each type of modification of imiglucerase treatment during the supply constraint.
ERT: enzyme replacement therapy.
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few data were available for TRAP analysis and no quan-
titative measures of bone involvement were systematic-
ally evaluated.
In the subgroup of 61 patients who discontinued imi-
glucerase, the models showed a statistically significant
decrease in hemoglobin (p = 0.003) with a slope estimate
of −0.8 g/L/month, and in platelets (p = 0.002) with a
slope estimate of −5905.103/mm3/month. There was a sta-
tistically significant increase in chitotriosidase (p = 0.021)
and in ACE (p = 0.012), but only 16 patients had available
data for ACE.
Changes over time observed in the models for
hemoglobin, platelets, ferritin, chitotriosidase and ACE
in the subgroup of 32 patients treated with a reduced
imiglucerase dose were not statistically significant.
Spontaneously reported GD-related events
Events reported during the whole supply constraint
period From the first modification for a given patient
until the end of the constraint period (31 October 2010),
64 GD-related events were spontaneously reported by
the investigators for 39 patients (39%) (Table 4). The
majority of these events (84%) were of mild or moderate
intensity. Most events resolved (32 events, 50%) or im-
proved (16 events, 25%), one event (1.6%) aggravated,
and the remaining (15 events, 23.4%) persisted without
change (terms reported by investigators were “ongoing,”
“stable,” “persisting,” and “no change”). Among these
GD-related events, 8 bone events were spontaneously re-
ported by the investigators in 8 patients: bone infarction
(four patients), and osteonecrosis, femur fracture, hand
fracture and rib fracture (one patient each). All patientsexcept one had previous history of bone impairment.
Two events of severe intensity (bone infarction and rib
fracture) led to a significant deterioration of the patient’s
health, according to the physician.
Three patients reported visceral events (hepatomegaly
with or without splenomegaly), but none were of severe
intensity.
Apart from these events of special interest, the most
frequently reported GD-related event was asthenia/fa-
tigue (8%). Some biological changes were also spontan-
eously reported by the investigators, the most frequent
being thrombocytopenia, increased serum ferritin (each
reported in 5% of the whole study population) and in-
creased chitotriosidase (4%). Overall, hematological events
were reported for 11 patients (11%).
GD-related events reported during the limited
constraint period: comparison between the subgroup of
patients who discontinued imiglucerase and the
subgroup of patients treated with a reduced dose of
imiglucerase.
As shown in Table 3, the percentage of patients who
experienced at least one GD-related event during the
constraint period that was limited to the duration of the
first stable modification (median time 5.1 months for pa-
tients who discontinued and 6 months for patients with
a reduced dose) was similar for the two subgroups of pa-
tients who discontinued imiglucerase and patients
treated with a reduced dose (24.6% and 21.9%, respect-
ively) of imiglucerase. No bone, hematological or visceral
event led to significant deterioration of health in either
subgroup, although the median duration of this period
Table 3 Description of the constraint period limited to duration of first stable modification*
Patients who discontinued
imiglucerase (N = 61)
Patients receiving a reduced
imiglucerase dose (N = 32)
Imiglucerase treatment
n Median (range) n Median (range)
Time between treatment start and
first modification (years)
9.7 (1; 14) 8.4 (1; 13)
Duration of the limited period of
constraint (months)
5.1 (3; 15) 6.0 (3; 15)
Imiglucerase dose (U/kg/4-weeks):
At treatment initiation 58 118.5 (51; 246) 31 113.1 (58; 267)
At pre-constraint timepoint 56 89.4 (10; 223) 32 94.7 (46; 239)
At first modification 61 0.0 (0.0; 0.0) 32 52.4 (32; 181)
Dose decrease from pre-constraint dose (%): n (%) patients
<25% 8 (25.0%)
≥25%; <50% 13 (40.6%)
≥50%; <75% 11 (34.4%)
Evolution of biological parameters
n Slope Estimate (SE) Time-effect (p-value) n Slope Estimate (SE) Time-effect (p-value)
Hemoglobin (g/L) 47 −0.8 (0.2) 0.003 26 0.6 (0.4) 0.196
Platelets (103/mm) 47 −5905 (1721) 0.002 26 1762 (1720) 0.322
Serum ferritin (μg/L) 22 12.4 (6.4) 0.078 10 −3.4 (13.3) 0.812
Chitotriosidase (nmol/mL/h) 31 537 (208) 0.021 15 179 (259) 0.510
ACE (IU/L) 16 3.6 (1.1) 0.012 11 −2.8 (1.9) 0.228
Spontaneously reported GD-related events (by MedDRA Preferred Term)
Number (%) of patients Number (%) of patients
All events 15 (24.6%) 7 (21.9%)
Bone events
Bone infarction 1 (1.6%) -
Hand fracture 1 (1.6%) -
Hematological events
Thrombocytopenia 3 (4.9%) 1 (3.1%)
Pancytopenia 1 (1.6%) -
Epistaxis 1 (1.6%) 1 (3.1%)
Gingival bleeding 1 (1.6%) -
Hematoma 1 (1.6%) -
Visceral events
Hepatomegaly - 1 (3.1%)
Other events
Asthenia/ Fatigue 4 (6.6%) 3 (9.4%)
Bone pain 2 (3.3%) 1 (3.1%)
Musculoskeletal pain - 1 (3.1%)
Arthralgia 1 (1.6%) -
Serum ferritin increased - 2 (6.3%)
ACE increased - 1 (3.1%)
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Table 3 Description of the constraint period limited to duration of first stable modification* (Continued)
Chitotriosidase increased 1 (1.6%) -
Parkinson’s disease 1 (1.6%) -
Stress 1 (1.6%) -
*”First stable modification” refers to discontinuation or reduced dose for at least 3 consecutive months.
Numerical values in bold print indicate statistical significance.
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clinically significant weight gain, weight remained mostly
stable over time in both subgroups.
According to Kaplan-Meier estimation, the probability
that a patient would present with a bone, hematological,
or visceral event during the constraint was 23%. This
probability was 37% for patients who discontinued the
treatment for at least 3 consecutive months and 10% for
patients treated with a reduced dose compared to the
pre-constraint dose for at least 3 months (Figure 2).
Discussion
This observational, retrospective, multicenter, national
study evaluated the effects of the imiglucerase supply
constraint in France between June 2009 and November
2010. According to the data from the French GD regis-
try, 208 GD patients were treated with imiglucerase in
June 2009 [23]. The number of included patients (99 pa-
tients with GD1) represents half of the potential number
of eligible patients based on the French GD registry data.
This difference might be explained by the fact that both
physicians and patients may have been reluctant to par-
ticipate in this observational study during the constraint
period. Therefore, a selection bias in the population of
this study cannot be excluded. Following the EMA and
CETG recommendations, treatment was maintained for
patients with the most at risk disease forms and these
patients were less subject to dose reductions. The char-
acteristics of the patients included in the present study
were generally comparable to those reported for a larger
cohort in the French GD Registry [23], with slightly bet-
ter results for biological parameters.
In accordance with CETG recommendations on the
therapeutic management of pediatric patients during the
constraint period, none of the 10 patients under 18 years
old discontinued imiglucerase and all were treated with
a reduced dose of imiglucerase (17% to 58% dose reduc-
tion). The first treatment modification consisted of imi-
glucerase discontinuation for 34% of the whole study
population, and a reduced imiglucerase dose without the
introduction of another treatment for 66%. The dose re-
duction was over 50% compared to the pre-constrained
dose for nearly half of these patients. Progressive re-
supplying reduced the number of patients who had dis-
continued imiglucerase from 70% to 29% between 3 and
9 months after the first modification. A return to pre-constraint doses, or even higher doses, was possible for
18% to 26% of the patients 6 to 12 months after the first
modification. However, the available imiglucerase supply
decreased again in April 2010 and, at the last treatment
modification prior to 01 November 2010, 58% of pa-
tients had discontinued imiglucerase treatment, includ-
ing 37% who started treatment with another ERT, and
5% who started miglustat. These results were consistent
with the treatment recommendations issued in Septem-
ber 2010 by the EMA, which dictated a progressive re-
turn to normal dose for patients who were treated with
reduced doses, but no new initiation of treatment with
imiglucerase or switch back to imiglucerase for patients
who had discontinued.
It was anticipated that the impact of the imiglucerase
supply constraint on French Gaucher disease patients
would be difficult to interpret overall because of the
variability in local treatment management and the nu-
merous consecutive dose changes according to supply
availability. As a result, two subgroups of patients were
defined for this analysis: a subgroup of 61 patients who
discontinued imiglucerase, and a subgroup of 32 patients
who were treated with a reduced imiglucerase dose for a
period lasting a minimum of 3 consecutive months,
without addition of another treatment for Gaucher dis-
ease. Results for these subgroups were analysed for the
period of constraint limited to stable imiglucerase treat-
ment regimen, relative to each patient. Six patients were
not reported in the subgroups: 2 patients could not be
classified (no stable modification for at least 3 consecu-
tive months) and 4 patients took only miglustat for at
least 3 consecutive months.
This study has numerous methodological shortcom-
ings that limit the extent of interpretation, e.g., retro-
spective data collection, an imbalance in statistical
power between the two compared subgroups of patients
due to disproportionate sample size, a small number of
available data for some of the biological parameters
studied, and a limited robustness of statistical models
due to variability in the time of retrospective data collec-
tion. One should also mention that systematic quantita-
tive bone and visceral follow-up measures were not
available, which limited the outcome evaluation in the
study population.
Taking into account these limitations, the study results
indicate that treatment discontinuation has a greater
Table 4 GD-related events spontaneously reported
during the whole period of imiglucerase supply
constraint*
GD Type 1 (N = 99)
Number of
events
Number (%) of patients with
at least 1 GD-related event
All events 64 39 (39.4%)
Bone events 8 8 (8.1%)
Bone infarction 4 4 (4.0%)
Osteonecrosis 1 1 (1.0%)
Femur fracture 1 1 (1.0%)
Hand fracture 1 1 (1.0%)
Rib fracture 1 1 (1.0%)
Other spontaneously
reported events
Hematological events 12 11 (11.1%)
Thrombocytopenia
5 5 (5.1%)
Pancytopenia 1 1 (1.0%)
Epistaxis 3 3 (3.0%)




Haematoma 1 1 (1.0%)
Visceral events 4 3 (3.0%)
Hepatomegaly 2 2 (2.0%)
Hepatosplenomegaly
1 1 (1.0%)











Bone pain 4 4 (4.0%)
Osteopenia 3 3 (3.0%)
*Whole period of imiglucerase constraint refers to the period of time from first
modification due to constraint to 31 October 2010).
Events are presented by MedDRA Preferred Term.
It should be noted that several events could be reported in one patient. During
the considered period, a total of 64 events were reported in 39 patients: one
event was reported in 26 patients, two events were reported in 5 patients, three
events were reported in 4 patients and four events were reported in 4 patients.
*Sixteen other events (incidence <3%) were reported in a total of 12 patients
(12.1%). These events were: tendonitis, angiotensin converted enzyme
increased (2 patients each), arthralgia, back pain, coccydynia, musculoskeletal
pain, thrombocytosis, increased blood acid phosphatase, Parkinson’s disease,
sciatica, tremor, spontaneous abortion, stress, erectile dysfunction (1 patient each).
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sion of biological parameters. Indeed, a statistically sig-
nificant decrease in hemoglobin and platelet counts andan increase in chitotriosidase and ACE were observed in
the subgroup of patients who discontinued the treat-
ment for at least 3 consecutive months.
The results observed in this French study are consist-
ent with those reported on several smaller cohorts in
different countries. The impact of the supply constraint
has previously been described on 26 patients from Israel
who discontinued treatment with imiglucerase [24], 34
Italian patients with an imiglucerase dose reduction for
at least 1 year [25], 26 patients from Netherlands and
United Kingdom who switched from imiglucerase to
velaglucerase [26], 50 Spanish patients who discontinued
imiglucerase treatment or were treated with a reduced
dose (50% reduction for most) analysed during a 6-
month period [27], 24 Australian patients put on a “drug
holiday” during the supply constraint [28], and 14 pa-
tients from Taiwan who had their imiglucerase dose re-
duced from 60 to 30 U/kg/2-weeks [29]. The cohorts’
characteristics were mostly comparable to the French
cohort, but the imiglucerase doses before the constraint
were generally lower (median of 30 to 60 U/kg/4-weeks,
except for Taiwan with a median of 120 U/kg/4-weeks).
All these studies reported a significant increase in chito-
triosidase and slight decreases in hemoglobin and plate-
lets in patients who either discontinued the treatment or
had a pronounced dose reduction.
During the whole period analysed in this study,
hematological, visceral and bone events were spontan-
eously reported as GD-related events in 11%, 3% and 8%
of patients, respectively. It must be noted that, among
the 8 patients who experienced bone events during the
constraint period, all but one had reported a previous
history of bone events, and 50% had undergone total
splenectomy. Splenectomy and a history of bone events
before treatment initiation have been shown to be risk
factors for developing bone events, even under treat-
ment with ERT [23]. The rate of bone events observed
during the whole supply constraint period (8%) was not
superior to the rate observed during the 18-months pre-
constraint period (12%). However, the data reporting
was different between the two periods (systematic vs.
spontaneous reporting), therefore any comparison
should be made with caution. In addition, one should
have in mind that GD is a chronic disease with a very
high inertia; therefore, any impact (whether positive
under treatment or negative after treatment interrup-
tion) on the visceral and bone compartments may take
months or even years before it can be translated into
clinically observable changes.
Furthermore, GD-related events relying on imaging
data must be analysed with caution (e.g., spleen and liver
volumes, bone lesions, bone infiltration, bone mineral
density), because these data were not collected systemat-
ically in participating centers and the assessments were
Figure 2 Kaplan Meier curve of time to first occurrence of a bone, hematologic or visceral event.
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differences (e.g., machines, protocol, reader). Similarly, it
is unlikely that bone pain, whether localized or diffuse,
was homogenously assessed across centers. In addition
to limiting the extent to which clinical outcome can be
evaluated in this study, these observations highlight a
need for improvement regarding the systematic assess-
ment of splenic and hepatic volumes, and of bone lesion
progression using standardized magnetic resonance
imaging.
As for the limited (to a stable modification) constraint
period analysis, the percentage of patients who experi-
enced at least one GD-related event was similar for pa-
tients who discontinued imiglucerase and those treated
with a reduced dose (25% and 22%, respectively). How-
ever, according to Kaplan-Meier estimation, the prob-
ability for a patient to present a bone, hematological or
visceral event during the limited constraint period was
higher for patients who discontinued the treatment com-
pared to patients who were treated with a reduced dose:
37% and 10%, respectively. According to recommenda-
tions, patients who discontinued the treatment were the
ones with lesser disease burden, so an increase in GD-related events in this population compared to patients
treated with a reduced dose could be linked to treatment
discontinuation.
Taken altogether, these elements suggest that, in the
context of a limited supply, it is preferable to maintain
patients under treatment with reduced doses (or less fre-
quent infusions) than to discontinue treatment with imi-
glucerase. These results are in line with the studies
published before the supply constraint took place, which
suggested that disease progression resumes following
ERT interruption, and recommended avoiding this prac-
tice [30-33].
This study concerned a limited period of observation,
hence could not allow the evaluation of the long-term
impact of dose reduction. Some events, particularly bone
events, may arise even with treatment continuation [34]
or years after treatment discontinuation or reduction of
treatment.
These observations prove useful to depict how the
health care community can respond to such circumstances.
The convening of expert meetings at the European (EMA)
and French level (National Committee for GD Treatment
Evaluation in coordination with the National Medicine
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sentatives of pharmaceutical companies allowed a timely
issuing of treatment recommendations that, coupled with
close case-by-case management at each physician’s level,
limited the impact of the constraint on French Gaucher
patients. The situation is now back to normal in France,
allowing patients to return to their recommended imiglu-
cerase dose with proven efficacy, as mentioned in the
product Summary of Product Characteristics for imigluce-
rase [10]. In the context of full supply, appropriate individ-
ualized dosing is indeed necessary to achieve and
maintain long-term therapeutic goals, specifically skeletal
goals [12,13,15-18].
Conclusions
The imiglucerase supply constraint in France between
June 2009 and November 2010 involved a large inter-
individual variability in the therapeutic management of
patients with GD, with numerous treatment modifications
depending on supply availability. Overall, the joint recom-
mendations issued by the French Medicine Agency, the
National Committee for GD Treatment Evaluation, pa-
tient associations, and pharmaceutical companies allowed
for satisfactory management of GD patients during the
supply constraint in France while protecting the most vul-
nerable patients. Keeping in mind the methodological lim-
itations of this observational retrospective study without
long-term follow-up, imiglucerase dose decreases have
shown a lower impact on the clinical and biological out-
comes in this population compared to treatment discon-
tinuation. However, general effects, such as fatigue and
bone pain, reported in patients treated at a reduced dose
or with interrupted imiglucerase therapy emphasize the
importance of maintaining appropriate individualized
doses for each patient.
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